Intravenous  ||| S:0 E:12 ||| JJ
temsirolimus  ||| S:12 E:25 ||| NN
in  ||| S:25 E:28 ||| IN
cancer  ||| S:28 E:35 ||| NN
patients ||| S:35 E:43 ||| NNS
:  ||| S:43 E:45 ||| :
clinical  ||| S:45 E:54 ||| JJ
pharmacology  ||| S:54 E:67 ||| NN
and  ||| S:67 E:71 ||| CC
dosing  ||| S:71 E:78 ||| JJ
considerations  ||| S:78 E:93 ||| NNS
Temsirolimus ||| S:93 E:105 ||| NNP
,  ||| S:105 E:107 ||| ,
a  ||| S:107 E:109 ||| DT
highly  ||| S:109 E:116 ||| RB
specific  ||| S:116 E:125 ||| JJ
inhibitor  ||| S:125 E:135 ||| NN
of  ||| S:135 E:138 ||| IN
mammalian  ||| S:138 E:148 ||| JJ
target  ||| S:148 E:155 ||| NN
of  ||| S:155 E:158 ||| IN
rapamycin  ||| S:158 E:168 ||| NNS
( ||| S:168 E:169 ||| -LRB-
mTOR ||| S:169 E:173 ||| NNP
) ||| S:173 E:174 ||| -RRB-
,  ||| S:174 E:176 ||| ,
is  ||| S:176 E:179 ||| VBZ
a  ||| S:179 E:181 ||| DT
novel  ||| S:181 E:187 ||| NN
anticancer  ||| S:187 E:198 ||| VBZ
targeted  ||| S:198 E:207 ||| VBN
therapy  ||| S:207 E:215 ||| NN
with  ||| S:215 E:220 ||| IN
a  ||| S:220 E:222 ||| DT
new  ||| S:222 E:226 ||| JJ
mechanism  ||| S:226 E:236 ||| NN
of  ||| S:236 E:239 ||| IN
action ||| S:239 E:245 ||| NN
.  ||| S:245 E:247 ||| .
The  ||| S:247 E:251 ||| DT
prototype  ||| S:251 E:261 ||| JJ
mTOR  ||| S:261 E:266 ||| JJ
inhibitor ||| S:266 E:275 ||| NN
,  ||| S:275 E:277 ||| ,
oral  ||| S:277 E:282 ||| JJ
rapamycin ||| S:282 E:291 ||| NN
,  ||| S:291 E:293 ||| ,
is  ||| S:293 E:296 ||| VBZ
poorly  ||| S:296 E:303 ||| RB
soluble  ||| S:303 E:311 ||| JJ
and  ||| S:311 E:315 ||| CC
undergoes  ||| S:315 E:325 ||| JJ
extensive  ||| S:325 E:335 ||| JJ
first-pass  ||| S:335 E:346 ||| JJ
metabolism ||| S:346 E:356 ||| NN
,  ||| S:356 E:358 ||| ,
leading  ||| S:358 E:366 ||| VBG
to  ||| S:366 E:369 ||| TO
low  ||| S:369 E:373 ||| JJ
and  ||| S:373 E:377 ||| CC
potentially  ||| S:377 E:389 ||| RB
variable  ||| S:389 E:398 ||| JJ
absorption  ||| S:398 E:409 ||| NN
and  ||| S:409 E:413 ||| CC
exposure ||| S:413 E:421 ||| NN
.  ||| S:421 E:423 ||| .
For  ||| S:423 E:427 ||| IN
some  ||| S:427 E:432 ||| DT
tumors ||| S:432 E:438 ||| NNS
,  ||| S:438 E:440 ||| ,
maximizing  ||| S:440 E:451 ||| VBG
the  ||| S:451 E:455 ||| DT
bioavailability  ||| S:455 E:471 ||| NN
and  ||| S:471 E:475 ||| CC
dose  ||| S:475 E:480 ||| JJ
intensity  ||| S:480 E:490 ||| NN
via  ||| S:490 E:494 ||| IN
intravenous  ||| S:494 E:506 ||| NNS
( ||| S:506 E:507 ||| -LRB-
IV ||| S:507 E:509 ||| NNP
)  ||| S:509 E:511 ||| -RRB-
administration  ||| S:511 E:526 ||| NN
may  ||| S:526 E:530 ||| MD
provide  ||| S:530 E:538 ||| VB
optimal  ||| S:538 E:546 ||| JJ
clinical  ||| S:546 E:555 ||| JJ
benefit ||| S:555 E:562 ||| NN
.  ||| S:562 E:564 ||| .
Temsirolimus  ||| S:564 E:577 ||| NNP
is  ||| S:577 E:580 ||| VBZ
an  ||| S:580 E:583 ||| DT
ester  ||| S:583 E:589 ||| JJ
analog  ||| S:589 E:596 ||| NN
of  ||| S:596 E:599 ||| IN
rapamycin  ||| S:599 E:609 ||| NNS
that  ||| S:609 E:614 ||| WDT
retains  ||| S:614 E:622 ||| VBZ
its  ||| S:622 E:626 ||| PRP$
potent  ||| S:626 E:633 ||| JJ
intrinsic  ||| S:633 E:643 ||| JJ
mTOR  ||| S:643 E:648 ||| JJ
inhibitory  ||| S:648 E:659 ||| JJ
activity  ||| S:659 E:668 ||| NN
while  ||| S:668 E:674 ||| IN
exhibiting  ||| S:674 E:685 ||| VBG
better  ||| S:685 E:692 ||| JJR
solubility  ||| S:692 E:703 ||| NN
for  ||| S:703 E:707 ||| IN
IV  ||| S:707 E:710 ||| NNP
formulation ||| S:710 E:721 ||| NN
.  ||| S:721 E:723 ||| .
In  ||| S:723 E:726 ||| IN
the  ||| S:726 E:730 ||| DT
treatment  ||| S:730 E:740 ||| NN
of  ||| S:740 E:743 ||| IN
advanced  ||| S:743 E:752 ||| JJ
renal  ||| S:752 E:758 ||| JJ
cell  ||| S:758 E:763 ||| NN
carcinoma ||| S:763 E:772 ||| NN
,  ||| S:772 E:774 ||| ,
temsirolimus  ||| S:774 E:787 ||| NN
is  ||| S:787 E:790 ||| VBZ
administered  ||| S:790 E:803 ||| VBN
as  ||| S:803 E:806 ||| IN
a  ||| S:806 E:808 ||| DT
30-  ||| S:808 E:812 ||| NN
to  ||| S:812 E:815 ||| TO
60-minute  ||| S:815 E:825 ||| NNP
IV  ||| S:825 E:828 ||| NNP
infusion  ||| S:828 E:837 ||| NN
once  ||| S:837 E:842 ||| RB
weekly  ||| S:842 E:849 ||| JJ
at  ||| S:849 E:852 ||| IN
a  ||| S:852 E:854 ||| DT
flat  ||| S:854 E:859 ||| JJ
dose  ||| S:859 E:864 ||| NN
of  ||| S:864 E:867 ||| IN
25  ||| S:867 E:870 ||| CD
mg ||| S:870 E:872 ||| NNS
.  ||| S:872 E:874 ||| .
This  ||| S:874 E:879 ||| DT
dosage  ||| S:879 E:886 ||| JJ
results  ||| S:886 E:894 ||| NNS
in  ||| S:894 E:897 ||| IN
high  ||| S:897 E:902 ||| JJ
peak  ||| S:902 E:907 ||| NN
temsirolimus  ||| S:907 E:920 ||| NN
concentrations  ||| S:920 E:935 ||| NNS
and  ||| S:935 E:939 ||| CC
limited  ||| S:939 E:947 ||| JJ
immunosuppressive  ||| S:947 E:965 ||| JJ
activity ||| S:965 E:973 ||| NN
.  ||| S:973 E:975 ||| .
Because  ||| S:975 E:983 ||| IN
temsirolimus  ||| S:983 E:996 ||| NN
is  ||| S:996 E:999 ||| VBZ
active  ||| S:999 E:1006 ||| JJ
and  ||| S:1006 E:1010 ||| CC
well  ||| S:1010 E:1015 ||| RB
tolerated ||| S:1015 E:1024 ||| JJ
,  ||| S:1024 E:1026 ||| ,
different  ||| S:1026 E:1036 ||| JJ
dosages  ||| S:1036 E:1044 ||| NN
and  ||| S:1044 E:1048 ||| CC
schedules  ||| S:1048 E:1058 ||| NNS
are  ||| S:1058 E:1062 ||| VBP
being  ||| S:1062 E:1068 ||| VBG
explored  ||| S:1068 E:1077 ||| NN
for  ||| S:1077 E:1081 ||| IN
other  ||| S:1081 E:1087 ||| JJ
solid  ||| S:1087 E:1093 ||| JJ
and  ||| S:1093 E:1097 ||| CC
hematologic  ||| S:1097 E:1109 ||| JJ
malignancies ||| S:1109 E:1121 ||| NN
,  ||| S:1121 E:1123 ||| ,
including  ||| S:1123 E:1133 ||| VBG
mantle  ||| S:1133 E:1140 ||| JJ
cell  ||| S:1140 E:1145 ||| NN
lymphoma ||| S:1145 E:1153 ||| NN
.  ||| S:1153 E:1155 ||| .
Temsirolimus  ||| S:1155 E:1168 ||| NNP
exhibits  ||| S:1168 E:1177 ||| VBZ
a  ||| S:1177 E:1179 ||| DT
high  ||| S:1179 E:1184 ||| JJ
volume  ||| S:1184 E:1191 ||| NN
of  ||| S:1191 E:1194 ||| IN
distribution  ||| S:1194 E:1207 ||| NN
that ||| S:1207 E:1211 ||| IN
,  ||| S:1211 E:1213 ||| ,
together  ||| S:1213 E:1222 ||| RB
with  ||| S:1222 E:1227 ||| IN
IV  ||| S:1227 E:1230 ||| NNP
administration ||| S:1230 E:1244 ||| NN
,  ||| S:1244 E:1246 ||| ,
leads  ||| S:1246 E:1252 ||| VBZ
to  ||| S:1252 E:1255 ||| TO
extensive  ||| S:1255 E:1265 ||| JJ
distribution  ||| S:1265 E:1278 ||| NN
into  ||| S:1278 E:1283 ||| IN
peripheral  ||| S:1283 E:1294 ||| JJ
tissues ||| S:1294 E:1301 ||| NNS
.  ||| S:1301 E:1303 ||| .
In  ||| S:1303 E:1306 ||| IN
addition ||| S:1306 E:1314 ||| NN
,  ||| S:1314 E:1316 ||| ,
significant  ||| S:1316 E:1328 ||| JJ
and  ||| S:1328 E:1332 ||| CC
protracted  ||| S:1332 E:1343 ||| JJ
exposures  ||| S:1343 E:1353 ||| NNS
are  ||| S:1353 E:1357 ||| VBP
attained  ||| S:1357 E:1366 ||| VBN
with  ||| S:1366 E:1371 ||| IN
sirolimus  ||| S:1371 E:1381 ||| NNS
( ||| S:1381 E:1382 ||| -LRB-
rapamycin ||| S:1382 E:1391 ||| LS
) ||| S:1391 E:1392 ||| -RRB-
,  ||| S:1392 E:1394 ||| ,
the  ||| S:1394 E:1398 ||| DT
major  ||| S:1398 E:1404 ||| JJ
equipotent  ||| S:1404 E:1415 ||| JJ
metabolite  ||| S:1415 E:1426 ||| NN
of  ||| S:1426 E:1429 ||| IN
temsirolimus ||| S:1429 E:1441 ||| NN
.  ||| S:1441 E:1443 ||| .
Whereas  ||| S:1443 E:1451 ||| IN
temsirolimus  ||| S:1451 E:1464 ||| NN
and  ||| S:1464 E:1468 ||| CC
sirolimus  ||| S:1468 E:1478 ||| NNS
are  ||| S:1478 E:1482 ||| VBP
both  ||| S:1482 E:1487 ||| DT
metabolized  ||| S:1487 E:1499 ||| NN
by  ||| S:1499 E:1502 ||| IN
cytochrome  ||| S:1502 E:1513 ||| CD
P450  ||| S:1513 E:1518 ||| CD
( ||| S:1518 E:1519 ||| -LRB-
CYP ||| S:1519 E:1522 ||| NNP
)  ||| S:1522 E:1524 ||| -RRB-
3A4 ||| S:1524 E:1527 ||| NNP
,  ||| S:1527 E:1529 ||| ,
drug  ||| S:1529 E:1534 ||| NN
interaction  ||| S:1534 E:1546 ||| NN
studies  ||| S:1546 E:1554 ||| NNS
with  ||| S:1554 E:1559 ||| IN
agents  ||| S:1559 E:1566 ||| NNS
that  ||| S:1566 E:1571 ||| IN
induce  ||| S:1571 E:1578 ||| NN
or  ||| S:1578 E:1581 ||| CC
inhibit  ||| S:1581 E:1589 ||| VB
CYP3A4  ||| S:1589 E:1596 ||| CD
activity  ||| S:1596 E:1605 ||| NN
indicate  ||| S:1605 E:1614 ||| VBP
that  ||| S:1614 E:1619 ||| DT
exposure  ||| S:1619 E:1628 ||| NN
to  ||| S:1628 E:1631 ||| TO
the  ||| S:1631 E:1635 ||| DT
sirolimus  ||| S:1635 E:1645 ||| JJ
metabolite  ||| S:1645 E:1656 ||| NN
is  ||| S:1656 E:1659 ||| VBZ
somewhat  ||| S:1659 E:1668 ||| RB
sensitive  ||| S:1668 E:1678 ||| JJ
to  ||| S:1678 E:1681 ||| TO
pharmacokinetic  ||| S:1681 E:1697 ||| VB
( ||| S:1697 E:1698 ||| -LRB-
PK ||| S:1698 E:1700 ||| NNP
)  ||| S:1700 E:1702 ||| -RRB-
drug  ||| S:1702 E:1707 ||| NN
interaction ||| S:1707 E:1718 ||| NN
.  ||| S:1718 E:1720 ||| .
Therefore ||| S:1720 E:1729 ||| RB
,  ||| S:1729 E:1731 ||| ,
temsirolimus  ||| S:1731 E:1744 ||| JJ
dose  ||| S:1744 E:1749 ||| NN
adjustments  ||| S:1749 E:1761 ||| NNS
are  ||| S:1761 E:1765 ||| VBP
warranted  ||| S:1765 E:1775 ||| VBN
if  ||| S:1775 E:1778 ||| IN
coadministration  ||| S:1778 E:1795 ||| JJ
cannot  ||| S:1795 E:1802 ||| NNS
be  ||| S:1802 E:1805 ||| VB
avoided ||| S:1805 E:1812 ||| VBN
.  ||| S:1812 E:1814 ||| .
Despite  ||| S:1814 E:1822 ||| IN
its  ||| S:1822 E:1826 ||| PRP$
complexity ||| S:1826 E:1836 ||| NN
,  ||| S:1836 E:1838 ||| ,
the  ||| S:1838 E:1842 ||| DT
PK  ||| S:1842 E:1845 ||| NNP
profile  ||| S:1845 E:1853 ||| NN
of  ||| S:1853 E:1856 ||| IN
IV  ||| S:1856 E:1859 ||| NNP
temsirolimus  ||| S:1859 E:1872 ||| NN
is  ||| S:1872 E:1875 ||| VBZ
well  ||| S:1875 E:1880 ||| RB
characterized  ||| S:1880 E:1894 ||| VBN
in  ||| S:1894 E:1897 ||| IN
cancer  ||| S:1897 E:1904 ||| NN
patients  ||| S:1904 E:1913 ||| NNS
and  ||| S:1913 E:1917 ||| CC
provides  ||| S:1917 E:1926 ||| VBZ
a  ||| S:1926 E:1928 ||| DT
strong  ||| S:1928 E:1935 ||| JJ
basis  ||| S:1935 E:1941 ||| NN
for  ||| S:1941 E:1945 ||| IN
its  ||| S:1945 E:1949 ||| PRP$
future  ||| S:1949 E:1956 ||| JJ
study  ||| S:1956 E:1962 ||| NN
as  ||| S:1962 E:1965 ||| IN
a  ||| S:1965 E:1967 ||| DT
monotherapy  ||| S:1967 E:1979 ||| NN
or  ||| S:1979 E:1982 ||| CC
in  ||| S:1982 E:1985 ||| IN
combination  ||| S:1985 E:1997 ||| NN
with  ||| S:1997 E:2002 ||| IN
other  ||| S:2002 E:2008 ||| JJ
anticancer  ||| S:2008 E:2019 ||| JJ
agents ||| S:2019 E:2025 ||| NNS
.  ||| S:2025 E:2027 ||| .
